TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7742165
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration to healthy volunteers with behaviour pattern B
Study: 2373127
Drug: Cholestyramine 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 24 g/day for 4 days with piroxicam 20 mg p.o.
Study: 2373127
Drug: Cholestyramine 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 24 g/day for 4 days with tenoxicam 20 mg p.o.
Study: 6930320
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B - sequential regimens consisting of azacytidine, cyclophosphamide, prednisone, 6-mercaptopurine, methotrexate, plus BCG
Study: 24554519
Drug: Micronutrients (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients (various doses)
Study: 24554519
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonrandomized, no treatment)
Study: 24554519
Drug: Micronutrients (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients (continued treatment)
Study: 24554519
Drug: Micronutrients (stopped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients (stopped treatment)
Study: 17227493
Drug: Pharmacological androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological androgen deprivation (flutamide 250 mg orally three times/day and leuprolide acetate 7.5 mg injection) for 7 days
Study: 15202756
Drug: 35 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 percent hydrogen peroxide gel application for 30 minutes (Group 1)
Study: 15202756
Drug: 38 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 38 percent hydrogen peroxide gel application for 30 minutes (Group 2)
Study: 15202756
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent carbamide peroxide at-home bleaching agent for 60 minutes (combined with Group 1 and Group 2)
Study: 456997
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage haloperidol (50 to 100 mg daily)
Study: 456997
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (10 mg haloperidol and 150 to 300 mg levomepromazin)
Study: 31800306
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) up to 2700 mg/day for 12 weeks
Study: 25460556
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (HDDT) - rabeprazole 20 mg and amoxicillin 750 mg, 4 times/day for 14 days (group A1)
Study: 25460556
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy for 10 days (group B1)
Study: 25460556
Drug: Clarithromycin-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin-containing triple therapy for 7 days (group C1)
Study: 25460556
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (HDDT) for 14 days (group A2)
Study: 25460556
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy for 10 days (group B2)
Study: 25460556
Drug: Levofloxacin-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-containing triple therapy for 7 days (group C2)
Study: 16552832
Drug: SSP electro-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSP electro-therapy
Study: 10506613
Drug: Vinblastine (V)
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine (V) 4 mg/m(2) by intravenous bolus weekly for 6 weeks followed by 2 weeks off
Study: 10506613
Drug: Vinblastine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine plus estramustine phosphate (EM-V) 600 mg/m(2) PO days 1 through 42, repeated every 8 weeks
Study: 6822051
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of radioactive aerosol while sitting, lying, and breathing at an increased rate.
Study: 31683341
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg BD)
Study: 31683341
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metformin (500 mg BD) and Pioglitazone (15 mg BD)
Study: 31683341
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metformin and Pioglitazone
Study: 24865525
Drug: Intensive Repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Repeated Mailings (IRM) - 10 booklets and additional supplemental materials mailed monthly over 18 months
Study: 20170774
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy in addition to usual care
Study: 15790691
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (25‐100 mg)
Study: 10207355
Drug: Chemotherapy to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy to all household members at the commencement of the study (18-month interval)
Study: 10207355
Drug: Chemotherapy to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy to all household members at commencement and regular health education throughout the study period
Study: 10207355
Drug: Chemotherapy to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy to all household members at commencement and subsequent chemotherapy to all children at intervals of 6 months
Study: 10207355
Drug: Chemotherapy to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy to all household members at commencement, subsequent chemotherapy to all children at intervals of 6 months, and regular health education throughout the study period
Study: 7878975
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 3 × 10^8/kg unaltered donor bone marrow cells perioperatively
Study: 31756496
Drug: Brigatinib 90
Normalized name: brigatinib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 90 mg once daily (arm A)
Study: 31756496
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily with a 7-day lead-in at 90 mg (arm B)
Study: 28512009
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 50mg administered 1 hour before extinction training
Study: 25388434
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 2 kcal/min
Study: 21522004
Drug: Comparator (efavirenz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (efavirenz in STARTMRK; optimized background therapy in BENCHMRK)
Study: 11179521
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and phenprocoumon
Study: 7979564
Drug: Pulsatile oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile oxytocin infusion (one minute of infusion every five minutes)
Study: 2567190
Drug: Active depot
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active depot neuroleptic injections
Study: 2567190
Drug: Placebo depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo depot neuroleptic injections
Study: 60622
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (220 mg three times daily)
Study: 25609338
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy tablets containing birch and/or alder or grass pollen allergoids
Study: 21454917
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day) with gabapentin (up to 1,200 mg/day) for the first 6 weeks
Study: 21454917
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day) alone
Study: 18645136
Drug: High-dose UV‐A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UV‐A1 phototherapy (130 J/cm²)
Study: 18645136
Drug: Medium-dose UV‐A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose UV‐A1 phototherapy (65 J/cm²)
Study: 18645136
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose exposure (110-150 J/cm²)
Study: 16813176
Drug: Three-part massage
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-part massage therapy (acupoints at the head, abdomen, and back, once daily for 15 days)
Study: 16813176
Drug: Guipi Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guipi Pills (8 pills each time, thrice daily for 15 days)
Study: 16813176
Drug: Three-part massage
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-part massage therapy
Study: 12932752
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy for up to 24 months
Study: 11038198
Drug: Subtotal thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtotal thyroid resection (total remnant < 4 ml)
Study: 8777834
Drug: Intravenous noradrenaline
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous noradrenaline infusion
Study: 3903822
Drug: Combined estrogen-androgen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen-androgen preparation (E-A)
Study: 22770377
Drug: Salidroside (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salidroside (600 mg/day)
Study: 20581169
Drug: Imatinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 200 mg orally once daily (increased to 400 mg if well tolerated)
Study: 11419566
Drug: Metrifonate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (30 to 60 mg by weight or a 50-mg fixed dose once daily)
Study: 9521401
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin) 5,000 U once daily
Study: 9521401
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin 5,000 U twice daily
Study: 2681717
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin
Study: 2685951
Drug: Uniphyllin (UP)
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyllin (UP) taken as a single dose at bedtime
Study: 2685951
Drug: Slophyllin (SP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slophyllin (SP) taken twice daily
Study: 789170
Drug: N‐acetyl‐L‐glutamine aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐acetyl‐L‐glutamine aluminum complex (KW)
Study: 29392459
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored therapy plan and additional home visits (Intervention Group)
Study: 29392459
Drug: Standard German
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard German neurological treatment (Control Group)
Study: 26863146
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (15 sessions over 5 weeks focusing on stretching and strengthening exercises)
Study: 26863146
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (15 sessions including massage, mobilization, muscle energy and myofascial release)
Study: 24851039
Drug: Spasmofen rectal
Normalized name: atropine sulfate / hyoscyamine sulfate / phenobarbital / scopolamine hydrobromide Oral Tablet [Spasmolin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spasmofen rectal suppository (100 mg ketoprofen and 10 mg hyoscine butylbromide)
Study: 24851039
Drug: Ketorolac IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac IV (30 mg/2 mL)
Study: 24851039
Drug: Spasmofen rectal
Normalized name: atropine sulfate / hyoscyamine sulfate / phenobarbital / scopolamine hydrobromide Oral Tablet [Spasmolin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spasmofen rectal suppository
Study: 2023538
Drug: Pyridostigmine (PD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD), 120 mg administered orally
Study: 2023538
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two tablets administered orally
Study: 2023538
Drug: Saline, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, 1 mL injected as an IV bolus
Study: 6266897
Drug: pivmecillinam/pivampicillin (pivmecillinam
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam/pivampicillin (pivmecillinam 200 mg plus pivampicillin 250 mg) three times daily (14 patients)
Study: 6266897
Drug: pivmecillinam alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam alone (400 mg three times daily) (12 patients)
Study: 31253621
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) alone
Study: 9706932
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (1 g every 4 h)
Study: 10155674
Drug: Late rescue
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late rescue surfactant therapy
Study: 10155674
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment of severely ill neonates
Study: 10155674
Drug: Multiple-dose treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose treatments
Study: 10155674
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment surfactant therapy
Study: 10155674
Drug: Prophylaxis surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis surfactant therapy
Study: 10155674
Drug: Introduction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Introduction of porcine-derived lung surfactant (PLS) therapy
Study: 10155674
Drug: PLS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLS therapy
Study: 10155674
Drug: Costs for
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costs for PLS therapy
Study: 10155674
Drug: Additional costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional costs of PLS therapy per additional survivor
Study: 2350628
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy and total lymphoid irradiation with 750 cGy for severe aplastic anemia patients.
Study: 2350628
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy and single dose total body irradiation with 750-850 cGy for leukemia patients.
Study: 2350628
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy and fractionated total body irradiation with 1320 cGy for leukemia patients.
Study: 15037412
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of rosiglitazone daily for 3 months
Study: 3551675
Drug: Epidural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural pethidine 25 mg
Study: 31367733
Drug: Combined program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined program of textured lunch gatherings with oral and physical exercises (12-week program, twice a week)
Study: 25544263
Drug: neostigmine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine (70 μg/kg) and atropine (0.4 mg per mg neostigmine)
Study: 24085261
Drug: CYP3A4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP3A4 inhibitor (ketoconazole 400 mg daily for 10 days)
Study: 24085261
Drug: CYP3A4 inducer
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A4 inducer (rifampicin 600 mg daily for 14 days)
Study: 24085261
Drug: Midostaurin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin (single dose 100 mg and multiple doses 50 mg twice daily)
Study: 21392603
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (intravenous immunoglobulin and aspirin)
Study: 27784021
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment (monthly or individualized dosing)
Study: 27784021
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment (delayed responders)
Study: 24888911
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Foley catheter and low-dose vaginal misoprostol
Study: 24888911
Drug: Low-dose vaginal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaginal misoprostol alone
Study: 18654870
Drug: Threefold diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threefold diluted smallpox vaccine
Study: 18654870
Drug: Sixfold diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sixfold diluted smallpox vaccine
Study: 15971472
Drug: Fluticasone/salmeterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol combination via Diskus (n = 39) for 1 year
Study: 10556107
Drug: alpha(1)‐antitrypsin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha(1)‐antitrypsin infusion (250 mg/kg)
Study: 10556107
Drug: albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin infusion (625 mg/kg)
Study: 8818828
Drug: Oral co‐trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co‐trimoxazole 960 mg od or three times a week for primary and secondary prophylaxis
Study: 8818828
Drug: Co‐trimoxazole 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co‐trimoxazole 120 mg/kg/day in divided doses for 21 days
Study: 8818828
Drug: Oral dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dapsone with trimethoprim, oral clindamycin with primaquine, or IV pentamidine for mild or moderately severe disease
Study: 23484334
Drug: Single-dose Rifampicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose Rifampicin, Ofloxacin and Minocycline (ROM)
Study: 17638804
Drug: Single-dose cefmetazole
Normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefmetazole just before skin incision
Study: 17638804
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of cefmetazole (1 dose just before skin incision and 2 additional doses every 8 hours)
Study: 15047650
Drug: Vitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin therapy (vitamins C and E)
Study: 9796323
Drug: Heparin-coated Palmaz-Schatz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated Palmaz-Schatz stent
Study: 25451627
Drug: Jyoti meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jyoti meditation (8-week program with weekly 90-minute classes)
Study: 23331510
Drug: 600,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600,000 IU of Intramuscular vitamin D3
Study: 21702900
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) - 24 IU intranasal administration
Study: 17977662
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine 6 mg (total 48 mg over 4 days)
Study: 16671426
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Craniotomy for evacuation)
Study: 10781452
Drug: Protocol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol group (goal-oriented hemodynamic therapy)
Study: 8630614
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline sulphate via Turbuhaler (TBH)
Study: 8630614
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline sulphate via pMDI
Study: 8630614
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline sulphate via pMDI
Study: 8630614
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline sulphate via Turbuhaler (TBH)
Study: 1477308
Drug: 2-mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg dose of trihexyphenidyl
Study: 6398984
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Na (44 mmol) daily diet
Study: 3539897
Drug: Neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron therapy (d(15)+Be neutrons)
Study: 3539897
Drug: Photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon therapy (megavoltage photons)
Study: 29644408
Drug: Biomarker-driven maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-driven maintenance therapy
Study: 29644408
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction treatment